胸腺恶性肿瘤初诊胸膜转移的长期疾病特异性结局
该回顾性研究纳入1997年至2017年间因初诊胸腺恶性肿瘤伴胸膜转移接受切除术的72例患者,多数接受化疗和/或放疗,73%实现宏观完全切除。中位总生存11年,5年、10年、15年总生存率分别为73%、51%、18%,64%患者出现疾病进展。结论认为部分患者可通过积极多学科治疗获得长期生存甚至治愈。
要点
- 初诊胸膜转移的胸腺恶性肿瘤患者中位总生存达11年。
- 73%患者实现宏观完全切除,64%出现疾病进展。
- 积极多学科治疗可能使部分患者获得长期生存甚至治愈。
核心结论
- 胸腺恶性肿瘤伴胸膜或心包转移患者可获得长期生存,部分病例可能治愈。
研究设计与样本
- 回顾性研究纳入1997年5月至2017年12月间因初诊胸腺恶性肿瘤胸膜转移接受切除术的72例患者,排除胸腺切除术后胸膜复发者。
主要发现
- 72例患者中位年龄51岁(范围25-80),女性36例(50%);病理为胸腺瘤57例(79%)、胸腺癌15例(21%)。
- 52例(73%)实现宏观完全切除;5年、10年、15年总生存率分别为73%、51%、18%,中位总生存11年(中位随访5.9年)。
临床怎么用
- 对选择性初诊胸膜转移的胸腺恶性肿瘤患者,可考虑积极的多学科治疗包括手术切除。
局限性
- 回顾性设计,样本量有限,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment of patients with thymic malignancies metastatic to the pleura or pericardium is challenging, and benefits of aggressive treatment are unclear. We sought to characterize the long-term outcomes in this population. METHODS: We retrospectively identified patients who underwent resection for de novo thymic malignancies metastatic to the pleura between May 1997 and December 2017. Patients with pleural recurrence after prior thymectomy were excluded. Patient demographics, perioperative treatments, pathologic findings, and postoperative outcomes were collected. Descriptive statistics and Kaplan-Meier analyses were performed. RESULTS: Seventy-two patients were included (median age, 51 years [range 25-80]; 36/72 women [50%]). Pathologic diagnosis was thymoma in 57 patients (79%) and thymic carcinoma in 15 patients (21%). Most patients (67/72; 93%) received chemotherapy, radiation, or both. Forty-eight patients underwent thymectomy with pleurectomy, 7 patients underwent extrapleural pneumonectomy, 10 patients underwent thymectomy alone, and 7 patients were unresectable. Macroscopic complete resection was achieved in 52 patients (73%). Five-, 10-, and 15-year overall survivals were 73%, 51%, and 18%, respectively, and median overall survival was 11 years (median follow-up, 5.9 years). Forty-six patients (64%) had disease progression (median time to progression, 2.2 years). Repeat episodes of progression and treatment were common (median, 3 episodes/patient). The longest disease-free interval was 12.4 years. Thirteen patients (18%) remain disease-free; 7 patients (10%) were disease-free for more than 5 years. The longest ongoing survival without progression or reintervention is 9.9 years. CONCLUSIONS: Prolonged survival and, in some cases, cure can be achieved in patients with thymic malignancies metastatic to the pleura or pericardium. Aggressive multimodality therapy may be appropriate for select patients.
引用
- Choe G, Ghanie A, Riely G, et al. Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. J Thorac Cardiovasc Surg. 2019. PMID: 31610957. doi:10.1016/j.jtcvs.2019.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。